Transforming infectious disease diagnostics
ShanX Medtech develops an innovative In-Vitro Diagnostic solution that deliver ultra-rapid and accessible antimicrobial susceptibility testing. This supports global efforts to combat antimicrobial resistance by adressing current AST delays with trial-and-error prescribing – enabling targeted therapy at first contact.
Why we’re investing in ShanX
ShanX shows superior applicability and validated clinical performance at a low cost. With an experienced and high-profile team, Shanx is positioned to transform infectious disease diagnostics at the point-of-care. Strong data combined with strong commercial traction shows the promise further.